CD8A and neoplasm: Figure 4B shows that a significant population of TRP-2 antigen-specific CD8+ T cells is present in tumor-free surviving mice, 120 days following the first melanoma inoculation and 85 days after MIC treatment cessation. Recognition of the control H2-Kb/OVA257-264-tetramer by peripheral blood T cells of these mice was negative (data not shown).